NCT06580223Not yet recruitingPhase 3
Aspirin or Rivaroxaban Thromboprophylaxis for Patients With Multiple Myeloma
Aspirin or Rivaroxaban Thromboprophylaxis for Patients With Multiple Myeloma: A Prospective, Multicenter, Open-Label, Randomized Trial
Source: ClinicalTrials.gov · Last updated 18 Jul 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The aim of this study is to evaluate the efficacy and safety of aspirin and rivaroxaban in thromboprophylaxis in Chinese MM patients at high risk for MM-associated VTE.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 530 (estimated)
- First submitted
- 28 Aug 2024
- Start date
- 1 Sept 2025
- Primary completion date
- 1 Sept 2027
- Lead sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- Diseases
- Multiple myeloma
- NCT number
- NCT06580223
What you commit to
- Study type: Interventional · Phase 3
- Planned participants: 530
- From 1 Sept 2025 to the primary completion date, 1 Sept 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Active bleeding
- Patients already on antiplatelet therapy for other cardiovascular or cerebrovascular diseases.
Lab values
- When initiating treatment, platelet count below 50 G/L, or with PT prolonged by more than 3 seconds, and APTT prolonged by more than 10 seconds.
- Abnormal liver function (ALT or AST greater than 3 times the upper limit of normal, or total bilirubin greater than 2 times the upper limit of normal)
- Abnormal renal function (creatinine clearance \< 30 mL/min)
Other
- Pregnant women or women who are breastfeeding
- Active gastrointestinal ulceration
- Unable to cooperate in completing the clinical trial
- Already enrolled in other clinical studies
- Diagnosed with smoldering multiple myeloma or plasma cell leukemia
Who the study is looking for
- Newly diagnosed multiple myeloma (according to Guidelines for the diagnosis and management of multiple myeloma in China (2022 revision))
- High risk of VTE (according to Expert consensus on the prevention and treatment of multiple myeloma related venous thromboembolism in China (2022))
- Life expectancy exceeding 12 months
- Gender: not specified, Age: 18-90 years
- Serum HIV antigen or antibody negative
- HCV antibody negative, or HCV antibody positive with HCV RNA negative
- Echocardiogram shows a left ventricular ejection fraction of ≥50%
- Ability to sign an informed consent form
Age in the registry: 18 years to 90 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Coordinator of this site? Confirm its status | Wuhan | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.